CDC42 and neoplasm: We also performed daily tail vein injection of a second CDC42 lead inhibitor (ARN25062) and ARN22089 and observed that both compounds stunted tumor growth (Figure S3A) and reduced vessel arborization in tumors grossly (Figure S3B).